Brief: Freeline Therapeutics Holdings Reports First Quarter 2023 Financial Results

Freeline Therapeutics Holdings

30/05/2023 12:47

May 30 (Reuters) - Freeline Therapeutics Holdings Plc
 FRLN.O :
    * FREELINE REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS AND
BUSINESS HIGHLIGHTS
    * Q1 EARNINGS PER SHARE $0.02
    * REGAINED COMPLIANCE WITH NASDAQ LISTING REQUIREMENTS
    * EXPECT TO REPORT INITIAL CLINICAL DATA FOR FLT201 IN
GAUCHER
DISEASE IN Q3 OF 2023
    * FREELINE THERAPEUTICS HOLDINGS - EXPECTS CURRENT LEVEL OF
CASH
AND CASH EQUIVALENTS WILL ENABLE CO TO FUND PLANNED OPERATIONS
INTO Q2 OF 2024
    * AS OF MARCH 31, 2023, UNRESTRICTED CASH AND CASH
EQUIVALENTS
WERE $55.4 MILLION
    * Q1 EARNINGS PER SHARE VIEW $-3.10 -- REFINITIV IBES DATA

Source text for Eikon:  ID:nGNX97L3Wd 
Further company coverage:  FRLN.O 

 ((Reuters.Briefs@thomsonreuters.com;))